BMS Prepares To Move Opdivo Into Neoadjuvant Lung Cancer

 
• By Joseph Haas
  
Lung Cancer
BMS is looking to move into earlier lines of NSCLC therapy with Opdivo

More from Immuno-oncology

More from Anticancer